
Contents

1	Cancer Overdiagnosis and Overtreatment.	1
	Laurence Klotz	
2	Can We Screen and Still Reduce Overdiagnosis?	9
	Peter Ka-Fung Chiu and Monique J. Roobol	
3	The Role of Fear in Overdiagnosis and Overtreatment	21
	Iona Heath	
4	Ethical and Legal Considerations in Active Surveillance for Prostate Cancer.	31
	Lionne D.F. Venderbos	
5	Gleason 6 Tumors Should Still Be Labeled as Cancer.	41
	Angelo M. De Marzo and Jonathan I. Epstein	
6	Risk-Based Selection for Active Surveillance	53
	Jan F.M. Verbeek, Monique J. Roobol, and Ewout W. Steyerberg	
7	Surveillance at the Margins: Management of High-Volume Gleason 6, PSA > 10, or Gleason 3 + 4	65
	Laurence Klotz	
8	How Should Patients on Active Surveillance Be Followed?	71
	Frank-Jan H. Drost, Monique J. Roobol, and Leonard P. Bokhorst	
9	Triggers for Intervention	83
	Tuomas Mirtti, Hanna Vasarainen, and Antti Rannikko	
10	MR Imaging in Prostate Tumor Volume Assessment: How Accurate?	95
	Ivo G. Schoots and Theo H. van der Kwast	
11	Can MRI Replace Biopsy in Men on Surveillance?	111
	Francesco Giganti, Vasilis Stavrinides, and Caroline M. Moore	
12	Tissue-Based Markers for Risk Prediction.	121
	Chad A. Reichard and Eric A. Klein	

13	International AS Registry: The Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative	135
	Sophie M. Bruinsma, Daan Nieboer, Tim Hulsen, Liyang Zhang, Rachelle Kirk-Burnnand, Sam Gledhill, and Mark Buzza	
14	Better-Informed Decision-Making to Optimize Patient Selection	149
	Lara Bellardita, Paola Dordoni, Letizia De Luca, Julia Paola Menichetti Delor, and Riccardo Valdagni	
15	How Does QoL Compare Between Surveillance and Active Treatment?	169
	Lionne D.F. Venderbos, Stephanie D. Brandhof, and Ida J. Korfage	
16	The Potential Benefits of Diet and Physical Activity Among Active Surveillance Patients with Low-Burden Prostate Cancer	183
	Stacey A. Kenfield, David Tat, and June M. Chan	
17	Is There a Role for Pharmacologic Manipulation to Prevent Progression in Men on Active Surveillance? The Role of 5-ARIs, Statins, and Metformin	199
	Roy Mano and David Margel	
18	The Update of Active Surveillance Around the World: Utilization and Outcomes	207
	Jeffrey J. Tosoian, Ridwan Alam, Abbey Lepor, and Stacy Loeb	
19	Tissue Preservation: Active Surveillance and Focal Therapy as Complimentary Strategies	217
	Juan Gómez Rivas and Mark Emberton	
20	The Economics of Active Surveillance for Prostate Cancer	229
	Robert B. Lurvey and Marc A. Dall'Era	
21	Research Questions in Active Surveillance	239
	Laurence Klotz	
	Index	243

Active Surveillance for Localized Prostate Cancer

A New Paradigm for Clinical Management

Klotz, L. (Ed.)

2018, XII, 250 p. 39 illus., 27 illus. in color., Hardcover

ISBN: 978-3-319-62709-0

A product of Humana Press